抗癌药 SCIE

期刊简介预计审稿时间： 偏慢,4-8周

Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.

《抗癌药物》报道与抗癌药物相关的临床和实验结果，并欢迎有关抗癌药物设计、药物输送、药理学、激素和生物学方式以及化疗评估的投稿。《抗癌药物》是一份国际公认的期刊，致力于快速发表抗癌治疗剂的创新研究，旨在促进和报道有毒和无毒抗癌剂的研究。因此，该期刊的范围将涵盖传统的细胞毒性化疗和激素或生物反应方式，如白细胞介素和免疫疗法。提交的文章将由编辑进行初步审查。有些文章可能会退还给作者，无需进一步考虑。那些正在考虑发表的文章将由编辑和受邀的审稿人进行进一步评估和同行评审。

《Anti-cancer Drugs》(抗癌药)编辑部通讯方式为LIPPINCOTT WILLIAMS & WILKINS, 530 WALNUT ST, PHILADELPHIA, USA, PA, 19106-3621。如果您需要协助投稿或润稿服务，您可以咨询我们的客服老师。我们专注于期刊投稿服务十年，熟悉发表政策，可为您提供一对一投稿指导，避免您在投稿时频繁碰壁，节省您的宝贵时间，有效提升发表机率，确保SCI检索（检索不了全额退款）。我们视信誉为生命，多方面确保文章安全保密，在任何情况下都不会泄露您的个人信息或稿件内容。